Hello, everyone, and welcome to another working week. We hope the weekend respite was relaxing and invigorating, because that oh-so familiar routine of online calls, meetings, and deadlines has predictably returned. But what can you do? The world, such as it is, continues to spin. So to cope, we are brewing the mandatory cups of stimulation to provide some relief. Our choice so far today is old-fashioned hazelnut, a comforting touch. Feel free to join us. Remember, no prescription is required, so no rebate is necessary. Meanwhile, here are some tidbits for you to peruse. We hope you have a smashing day and, of course, do stay in touch. We enjoy your telegrams. …
People who received the Pfizer (PFE)-BioNTech (BNTX) vaccines may get as much benefit from a Johnson & Johnson (JNJ) booster shot as a Pfizer one, The New York Times explains, citing the findings of a small study released on Sunday. Researchers at Beth Israel Deaconess Medical Center in Boston studied 65 people who had received two shots of the Pfizer vaccine. Six months after the second dose, the researchers gave 24 of the volunteers a third dose of the Pfizer vaccine and gave 41 the Johnson & Johnson shot. The study was funded in part by Johnson & Johnson and has not yet been published in a scientific journal.
Public health experts and patient advocates say that promising Covid-19 treatment pills are likely to take longer to reach patients in low- and middle-income countries than in rich ones because of manufacturing and pricing obstacles, despite efforts by drug makers to make them more available, The Wall Street Journal writes. The generic drug makers need several months to ramp up their manufacturing, and the prices they set may still be too expensive for certain poor countries. Adding to the challenges, advocates and experts say, most low-income countries lack adequate testing and diagnostic tools to identify patients early enough for the treatments to help.
Create a display name to comment
This name will appear with your comment